Intraventricular Nicardipine for Aneurysmal Subarachnoid Hemorrhage Related Vasospasm: Assessment on Clinical Outcomes of Stroke by 30 & 90 Days


About this study

The purpose is to study the effects of intraventricular nicardipine, a vasodilatory agent, on VP and secondary outcomes of stroke and functional outcome at 30 and 90 days compared to those not treated with this agent.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  1. Aneurysmal or arteriovenous malformation (AVM)-related subarachnoid hemorrhage, with CTA or digital subtraction angiogram evidence of intracranial aneurysm or AVM
  2. Patients with EVD placed by clinical criteria
  3. Patients age 18 years or older
  4. Documented or abstracted Modified Rankin Scores (MRS) and Glasgow Outcomes Scale (GOS) scores during admission and at 30 (or if 30 day data not available, then mRS at discharge) and 90 days

Exclusion Criteria:

  1. Patients being treated with intraventricular antibiotics for bacterial meningitis related vasospasm
  2. Patients without arterial bleeding subarachnoid hemorrhage (non-aneurysmal, non-AVM) or vasospasm due to another cause
  3. Pregnant patients

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Jacksonville, Fla.

Mayo Clinic principal investigator

William Freeman, M.D.

Closed for enrollment

More information


Publications are currently not available

Mayo Clinic Footer